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EDITORIAL
Prehospital thrombolysis
Harvey D White, Director of Coronary Care and Cardiovascular Research, Green Lane Hospital,  Auckland.
between pain onset and thrombolytic therapy. In particular,
the GREAT Trial, where there was a two-hour delay in
treatment (similar to the Coromandel experience), found
that there was a 44% reduction in mortality with prehospital
thrombolysis,6 which could translate into 7-8 lives saved per
100 patients treated per year.
It is encouraging to note that there were no episodes of
ventricular fibrillation in the Coromandel study, as this has
been a concern with very early administration of
thrombolytic therapy, leading to the recommendation that
ambulances should be double-manned and carry
defibrillators.2
An alternative approach would be to transfer all patients
to a hospital with angioplasty facilities, but this would
mean that many patients would not receive any
reperfusion therapy for at least 90 minutes.7 Besides, most
hospitals in New Zealand do not have the facilities to
perform primary angioplasty, and those that do sometimes
find it difficult to maintain a 24-hour service. A recent
meta-analysis of ten trials showed that patients treated by
primary angioplasty had long-term mortality rates similar
to those treated with thrombolytic therapy.8 Modern
reperfusion strategies such as bolus administration of
reteplase can produce full epicardial coronary artery
reperfusion in 43% of patients by 30 minutes,9 and
regimens combining a thrombolytic agent with a IIb/IIIa
receptor antagonist achieve full reperfusion in about 80%
of patients at 90 minutes, with enhanced myocyte
reperfusion.10 The optimal strategy may include both
thrombolytic therapy and angioplasty (known as
facilitated angioplasty), which has been shown to be safe
and to achieve earlier restoration of epicardial blood
flow.11
While doctors continue to research and debate the merits
of different reperfusion strategies, late patient presentation
remains the greatest barrier to myocardial salvage,
particularly in rural communities. Mass media campaigns
have been run to encourage patients with suspected heart
attacks to present earlier for treatment, with some initial
success, but the message tends to be forgotten unless the
campaigns are repeated every so often.12
Guidelines for the administration of thrombolytic therapy by
New Zealand GPs are currently being developed. Patients with
suspected acute myocardial infarction should initially be given
pain relief, oxygen and an aspirin to chew. If the hospital is less
than one hour away, the patient should be transported there
immediately. If the expected transport time is greater than one
hour, an ECG should be recorded and transmitted to the
hospital for advice regarding the appropriateness of prehospital
thrombolysis. But this initiative will all come to nothing if the
funding agencies fail to ensure funding for bolus thrombolytic
agents, as has unfortunately happened in Coromandel. It is to
be hoped that rural New Zealanders suffering heart attacks will
New Zealand is a country with many rural communities,
some at considerable distance from a base hospital. Twenty
New Zealanders die from acute myocardial infarction every
day, making it one of our commonest causes of death. It is
well established that thrombolytic therapy reduces mortality
and helps to preserve left ventricular function, but its
efficacy attenuates markedly the longer that treatment is
delayed after the onset of acute coronary occlusion.1,2 If
patients receive treatment within the first (or ‘golden’) hour,
the risk of mortality can be halved,3,4 but for every hour of
delay, 2-5 lives are lost per 1000 patients treated.1,4,5 Patients
further than one hour’s travel from hospital therefore have
much to gain from prehospital thrombolysis.
In this issue of the Journal, Nunn and colleagues describe
a meticulous pilot study of prehospital thrombolysis by
general practitioners (GPs) in the Coromandel region.
Comparison with a control group of patients from the same
area who received thrombolysis in hospital between 1993
and 1998 showed that prehospital thrombolysis halved the
delay from symptom onset to treatment (135 minutes versus
270 minutes), with no arrhythmias during transport and no
hospital deaths. This was not a randomised study, but it
shows that prehospital thrombolysis is logistically possible in
this country, and results in markedly shorter ‘pain to needle’
times.
GPs in other parts of New Zealand (eg, Takaka,
Westport, Queenstown and Wanaka) have also had
experience in prehospital thrombolysis, using treatment
algorithms tailored to local needs.
In the Coromandel study, patients were given
thrombolytic therapy and then immediately transported
to hospital by rescue helicopter or ambulance (without
Advanced Care Officers). Elsewhere, patients have been
given thrombolytic therapy and then observed for one
hour before being transferred to hospital, or were
accompanied by the GP during transfer. The
thrombolytic agent used in Coromandel was reteplase, a
deletion mutant of tissue plasminogen activator that can
be administered as a bolus. Bolus thrombolytics have
important advantages for prehospital administration, such
as ease of dosing and administration without the need for
intravenous lines, and a lower associated incidence of
hypotension than older agents like streptokinase. In
Coromandel the patient’s ECG was transmitted to
Waikato Hospital for confirmation of the diagnosis. In
other regions, the ECG was interpreted by the GP and
thrombolytic therapy was administered according to the
local treatment protocol.
Eight randomised trials have evaluated prehospital versus
in-hospital thrombolysis.2 Overall, prehospital thrombolysis
was shown to reduce mortality by 17%, saving sixteen lives
per 1000 patients treated. The trials that showed the greatest
benefit involved patients with more than one hour’s delay
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soon have access to the same standard of care as is currently
available to their urban counterparts.
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Parasite genome publication
Rival approaches to the way in which genome sequences are published are creating growing tension between scientists at the
sequencing centres and those who want to use the sequencing data to further their study of the organisms involved.
International consortia that are sequencing Plasmodium falciparum, a parasite that causes malaria, and Trypanosoma brucei
which causes sleeping sickness, are each currently engaged in heated arguments over the wisdom of publishing preliminary,
annotated sequences in advance of the completion of full sequences.
In each case, prominent biologists who specialize in the organism are pushing for early publication. But genome sequencing
centres say the publication of preliminary data could deprive their teams of the proper credit for the full, annotated sequence
when it is completed.
Claire Fraser, president of The Institute for Genomic Research at Rockville, Maryland, which is part of both consortia,
believes that if outside scientists publish preliminary annotations (proposed function of a stretch of DNA) based on raw
sequencing data made available voluntarily by the sequencing centres, the final complete sequence may never be published.
Colin Macilwain. Nature 2000; 405: 601.
No advantage in screening for endometrial cancer
No advantage exists in routine endometrial screening for patients with breast cancer who are being treated with tamoxifen,
according to two new studies.
Although taxmoxifen cuts the risk of breast cancer in some women, it also raises the risk of endometrial cancer. As a result,
patients taking the drug often undergo invasive and somewhat painful biopsies and ultrasound examination of the uterine
lining.
The new studies report that these commonly used screening methods are no more effective at diagnosing early endometrial
cancer in these patients than watching for abnormal vaginal bleeding. Researchers found that with high rates of false positive
results, the risks from both endometrial biopsy and transvaginal ultrasonography far outweigh the benefits.
J Clin Oncol 2000; 18: 3459-63 and 3464-70.
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Community thrombolysis in the Coromandel region. Audit of the “Cardiac Events
in the Coromandel – Assessment Strategy and Triage” (CE-COAST) pilot program
Chris Nunn, Cardiologist, Department of Cardiology, Waikato Hospital, Hamilton; John Lennane, General
Physician, Department of Medicine, Thames Hospital, Thames; Glen Marriott, General Practitioner, Coromandel
Medical Centre, Coromandel Township; David Wilson, General Practitioner, Mercury Bay Medical Centre,
Whitianga.
Abstract
Aim. To audit the experience of a pilot program for
community thrombolysis undertaken within the
Coromandel region.
Methods. Community thrombolysis for patients suffering
acute myocardial infarction (MI) was undertaken in areas within
the Coromandel peninsula greater than half an hour by road
from Thames Hospital. Thrombolytic therapy (Reteplase) was
given following discussion and review of a digitally transmitted
ECG with the cardiology registrar. Treatment times and
patient demographics were prospectively recorded. Subsequent
clinical events were obtained by chart review. Comparison of
treatment times were made with an historical cohort for the
same population which had received in-hospital thrombolysis
between 1993 and 1998.
Results. Between July 1998 and December 1999,
nineteen patients received thrombolysis in the
community. There were no arrhythmic events during
transportation and no deaths or reinfarctions during
hospital stay. Median time from pain onset to
thrombolysis was 135 (mean 175.5 ± 144.9 SD) minutes
which equated to a reduction in median time delay of 135
minutes compared to that experienced by the historical
cohort (median 270, mean 316.7 ± 145.8 SD minutes),
p=0.0003.
Conclusion. Community thrombolysis is logistically
feasible within the New Zealand setting and results in
major time reductions in the treatment of patients with
acute MI.
NZ Med J 2001; 114: 197-9
Thrombolytic therapy has been shown, over the past ten
years, to reduce mortality in patients suffering acute
myocardial infarction (MI).1-3 However, the extent to which
mortality is reduced attenuates with increasing delay from
onset of infarction to delivery of treatment.1,2,4,5 Delays in
accessing medical services, transportation to hospitals and
hospital triage processes all contribute to total time to
treatment.6 Rural communities are particularly
disadvantaged due to the greater distances from both general
practitioner (GP) services and base hospitals. A recent report
revealed an average delay of over five hours from pain onset
to thrombolysis for patients residing within the Coromandel
region.7
Several international studies have demonstrated the
feasibility and safety of pre-hospital assessment and initiation
of thrombolysis.8-18 Because of the considerable treatment
delays experienced by Coromandel patients, a pilot program
of community thrombolysis was established. We report the
first eighteen months experience of this program.
Methods
Local populations greater than half an hour from Thames hospital were
identified: Coromandel township, Whitianga, Tairua, Pauanui,
Whangamata, and Waihi. Following appropriate education, GPs from
these areas were supplied with a Lifepak-11 machine (Physio Control)
and Reteplase (Boehringer Mannheim). The Lifepac 11 ECG machine
was used in preference to fax transmission because of convenience
(allowing one step acquisition and subsequent transmission of the ECG)
and improved clarity of the received ECG. Due to limited supplies of the
Lifepak-11 machines, GPs in the same area shared machines on an on-
call basis. Because of the distance between Waihi beach and Waihi
township, sharing the Lifepac was impractical and thus only Waihi
township participated in the program.
Patients who presented to their GP with a possible acute MI had a 12
lead ECG which was transmitted via modem to the Waikato coronary
care unit (CCU). A direct phone line was set up along side the Lifepac
receiving station in CCU to allow unimpeded GP access. The on-call
registrar reviewed the ECG and discussed appropriateness of
thrombolytic therapy with the GP. In cases of diagnostic uncertainty the
registrar could obtain a cardiologist’s opinion. Indications for
thrombolytic therapy were: 1. A clinical history of ≥30 minutes of chest
discomfort beginning ≤6 hours previously or >6 hours if on-going pain
present. 2. An ECG showing ST-segment elevation of ≥1 mm in two or
more inferior leads, or ≥2mm in two or more anterior leads. 3. Absence
of contra-indications to thrombolysis.
Standard contraindication criteria were adhered to.1 Indications and
contraindications to thrombolytic therapy were discussed with the
cardiology registrar before a final treatment decision was made.
All patients received 300mg soluble aspirin as soon as a diagnosis of
acute MI was made. In those patients receiving thrombolysis, 5000 IU
intravenous heparin was given as a bolus injection. Due to the lack of
advanced care ambulance officers, intravenous infusions were unable to
be administered during transportation. Heparin infusions were therefore
commenced once the patient arrived at Thames Hospital. Thrombolytic
therapy was administered using Reteplase according to the
manufacturer’s guidelines. Two bolus doses were given 30 minutes apart.
The mode of patient transport was determined by the patient’s clinical
condition. Road transport by ambulance (unaccompanied by a doctor)
was preferred, but where there was haemodynamic instability and medical
supervision was required, helicopter retrieval was undertaken usually to
Waikato hospital.
GPs documented baseline demographic and clinical data including the
timing of onset of chest pain and treatments. Subsequent hospital events
and six month outcomes were obtained by phone and/or retrospective
chart review. All ECGs were reviewed subsequently by a cardiologist to
determine diagnostic accuracy.
An earlier historical review of acute MI management in the
Coromandel region between 1993 and 1998 provided detailed
information on treatment delays and this allowed comparisons to be made
with patients receiving community thrombolysis.7 Only patients residing
within the Coromandel region more than half an hour from Thames
hospital in the historical cohort were included in these comparisons.
Results
Between July 1998 and December 1999, there were 75
ECG transmissions to Waikato CCU, nineteen of which
met  criteria for acute MI (CE-COAST patients). One
patient with ST elevation anteriorly who was given
thrombolytic therapy was subsequently found to have
had an abnormal baseline ECG from an earlier infarct
and in fact did not suffer a further infarction. These data
ORIGINAL ARTICLES
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Figure 1. Time differences between patients receiving community
thrombolysis (CE-COAST) and historical cohort receiving hospital
thrombolysis.7
were included in the overall  results to allow an
intention-to-treat analysis.
Patient characteristics were typical of a cardiac care
population (Table 1). There was a trend to reduced heart
failure on admission in patients receiving community
thrombolysis compared to the historical cohort (21.1 % vs
44.2% respectively, p=0.069). Patient transportation was
uneventful following thrombolysis with no arrhythmic
events requiring treatment. There were no deaths or
reinfarctions during hospitalization. Average length of
hospital stay was 5.2 ± 1.8 days. Total creatine kinase
enzyme (CK) rise (excluding the non-infarct patient) was
relatively low (1924 units). This was skewed by two patients
with CK levels greater than 5000 units. Excluding these
patients the mean CK rise was only 1147 units. Only one
patient required in-hospital revascularization.
Table 1. Patient characteristics.
Community Thrombolysis Historical Cohort
(19) (77)
Age (yrs) 69.4±9.4 66.2±11.2
Male 13 (68.4%) 59 (76.6%)
Diabetic 0 6 (7.8%)
Smokers 3 (15.8%) 21 (27.3%)
Previous MI 7 (36.8%) 18 (23.4%)
Previous CABG 1 (5.3%) 1 (1.3%)
Heart failure on admission 4 (21.1%) 34 (44.2%)*
*CE-COAST vs historical cohort, p=0.069. Data are mean ±SD or %.
All ECG transmissions were successful except three, which
were faxed in the early phase of the program. These failures
were due to problems with the use of an external modem at
the receiving station. Review of all  ECGs revealed only one
inappropriate diagnosis as outlined earlier. No patient was
denied thrombolysis due to failure to diagnose an infarct
although two patients with equivocal ECGs initially had
developed an infarct pattern by the time of hospital arrival
and were given thrombolysis at that time.
Treatment Times. The initial mean delay to presentation
was 122.9 ± 142.8 (SD) minutes (median 65 minutes). The
other major delay was the time required for medical
assessment (29.0 ± 20.1 minutes). The total delay from pain
onset to thrombolysis was 175.5 ± 144.9 minutes, less than a
third of which (30.0%) comprised delays after initially
seeking medical attention (Table 2).
Historical Comparison. As previously reported,7 between
1993 and 1998, patients with acute MI  from within the
Coromandel region but living outside Thames and its
environs experienced a mean delay of 5 hours and 16
minutes between pain onset and in-hospital thrombolysis.
53.5% of this time comprised delays subsequent to the initial
medical assessment. The initial delay in seeking medical
attention was unchanged over this time period (Table 2).
However, patients thrombolysed in the community had
reduced medical assessment (hospital and GP) time (40.2 ±
20.7 vs 96.8 ± 40.9 mins, p<0.0001) and reduced travel time
(0 vs 72.6 ± 24.0 mins, p<0.0001) compared to the hospital
thrombolysed cohort, respectively. Total time therefore,
from pain onset to thrombolysis was reduced from 316.7 ±
145.8 minutes in the hospital treated patients to 175.5 ±
144.9 minutes in community treated patients, p=0.0003
(Figure 1). This resulted in a net median time saving of 135
minutes.
Discussion
Institution of thrombolytic therapy in the community
removes two sources of treatment delay. The first is patient
transportation, which is particularly important for areas at
considerable distance from a base hospital, and averages 72.6
minutes for Coromandel patients not living in Thames or its
environs.7 The second delay occurs once the patient reaches
the base hospital and averages between 45 and 90 minutes.19-
24 The experience at Thames hospital (60.5 ± 35.3 SD
minutes) is consistent with this.7 By instituting community
thrombolysis only one medical assessment is required. This
is undertaken by the GP in consultation with the base
hospital CCU. Repeat assessments are therefore avoided
resulting in a reduction in total medical assessment time of
56.6 minutes.
Table 2. Treatment delays prior to thrombolytic administration.
Community Thrombolysis Historical Cohort
Median* Mean† Median* Mean†
Pain onset to GP visit 65.0 (45,130) 122.89 ± 142.84 97.0 (50,231) 147.3 ± 136.4
GP visit to ECG 25.0 (15,45) 29.0 ± 20.05 34.0 (25,45) 36.6 ± 17.7
transmission or GP
assessment‡
ECG transmission to 9.0 (5,15) 11.21 ± 9.61 50.0 (40,75) 60.2 ± 36.6
diagnosis or hospital
triage time§
Transport time 0 0 65 (59,95) 72.6 ± 24.0
GP visit to lysis 50.0 (45,70) 52.63 ± 18.81 160 (136,189) 169.4 ± 45.9
Pain onset to lysis 135.0 (85,60) 175.53 ± 144.86 270 (220,395) 316.8 ± 145.8
* Median (25th,75th quartiles). † mean ± standard deviation. ‡ GP visit to ECG transmission for community thrombolysis patients or GP assessment for historical group. §
ECG transmission to diagnosis for community thrombolysis patients or hospital triage time for historical group.
Hisotrical cohort
Community thrombolysis
Pain to GP visit
p<0.0001
p<0.0001
p=0.0003
Medical
assessment
GP visit to lysis Pain onset to
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The impact of the 135 minute total reduction in treatment
delay can only be assessed by randomised trials of
community versus hospital thrombolysis. A meta-analysis  of
the eight completed trials revealed a 17% reduction in
mortality (p=0.02).9 Individually, however, the trials failed to
show an early mortality benefit due to a combination of
small sample sizes and relatively small time savings. Only
three trials enrolled more than 300 patients and all but two
had timesavings of less than one hour.8-10 The largest trial
was EMIP (5649 patients) which demonstrated a time saving
of 55 minutes9 with only a trend to reduced 30 day
mortality. The GREAT study on the other hand had a time
on saving of 130 minutes, similar to the CE-COAST
program, and demonstrated a divergence in mortality curves
with a very substantial late mortality benefit from early
thrombolysis. At 30 months, the benefit for patients who
presented one hour after pain onset was 80 lives saved per
1000 per hour.25
Clinical events during transportation and subsequent
hospitalisation in this report were low. Hospital stay was
only 5.2 ± 1.8 days, a reduction of two days compared to that
experienced over the previous five years (5.2 ± 1.8 vs 7.1 ±
2.8 days respectively, p=0.006).7 One concern, however, that
arises with community thrombolysis is early ventricular
fibrillation (VF). Whilst the EMIP study found an increased
incidence of early VF with community thrombolysis (2.5%
vs 1.6% in hospital patients, p=0.02) the overall incidence
was unchanged (6.2% vs 7.0%, p=0.23) due to the relative
excess occurring during hospitalisation in patients receiving
delayed thrombolysis.9 The increased incidence of early VF
highlights the need of defibrillation facilities and trained
personnel during initial GP assessment and subsequent
transportation.
This study is limited by small patient numbers and use of
an historical cohort. The numbers here, however, reflect the
largest experience of community thrombolysis reported to
date in Australasia. The use of an historical cohort does
allow confounding variables to influence treatment delays
independent of treatment location. The differences reported
here, however, are of such magnitude that the impact of
community thrombolysis is unlikely to be negated.
In conclusion, community thrombolysis is logistically
feasible and results in major timesavings for patients
otherwise disadvantaged by geography. At present the CE-
COAST program is suspended due to difficulties funding
thrombolytic agents for use in the community. Given the
timesavings and potential impact on short and long term
mortality, this is most unfortunate. New Zealand comprises
many populated rural areas, which would benefit from this
treatment. A national program should be instituted to
identify these areas and provide funding to allow all acute
infarct patients to receive appropriate therapy in a timely
and equitable fashion.
Acknowledgements. We gratefully acknowledge the assistance and advice
given by Dr Hamish Charleson in preparation of this manuscript. Lifepac II
machines were supplied by Physio Control via Pulse Data International Ltd
Auckland. Reteplase was supplied by Boehringer Mannheim via Roche
Pharmaceuticals, Auckland.
Correspondence. Dr Chris Nunn, Dept of Cardiology, Waikato Hospital,
Private Bag, Hamilton. Fax: (07) 839 8760.
1. Second International Study of Infarct Survival Collaborative Group. Randomised trial of
intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute
myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
2. Gruppo Italiano per lo studio della streptochinasi nell’infarto miocardico (GISSI).
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet
1986; 1: 397-401.
3. Wilcox RG, von der Lippe G, Olsson CG et al. Trial of tissue plasminogen activator for
mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early
Thrombolysis (ASSET). Lancet 1988; 2: 525-30.
4. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic
therapy in suspected acute myocardial infarction: collaborative overview of early mortality
and major morbidity results from all randomised trials of more than 1000 patients. Lancet
1994; 343: 311-22.
5. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic therapy in acute
myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-5.
6. Porter G, Doughty R, Gamble G, Sharpe N. Thrombolysis in acute myocardial infarction:
reducing in-hospital treatment delay. NZ Med J 1995; 108: 253-4.
7. Nunn C, Scott M, Lennane J. Treatment delays for acute infarct patients within the
Coromandel region of New Zealand. NZ Med J 2001; 114: 41-3.
8. Weaver WD, Cerqueira M, Hallstrom AP et al. For the Myocardial Infarction Triage and
Intervention Project Group. Pre-hospital-initiated vs hospital-initiated thrombolytic therapy.
JAMA 1993; 270: 1211-6.
9. The European Myocardial Infarction Project Group. Pre-hospital thromboltyic therapy in
patient with suspected acute myocardial infarction. N Eng J Med 1993; 329: 383-9.
10. The GREAT Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general
practitioners. BMJ 1992; 305: 548-53.
11. Castaigne AD, Hervé C, Duval-Moulin AM et al. Prehospital use of APSAC: results of a
placebo-controlled study. Am J Cardiol 1989; 64: 30A-3A.
12. McNeil AJ, Cunningham SR, Flannery DJ et al. A double blind placebo controlled study of
early and late administration of recombinant tissue plasminogen activator in acute myocardial
infarction. Br Heart J 1989; 61: 316-21.
13. Barbash GI, Roth I, Hod H et al. Improved survival but not left ventricular function with
early and prehospital treatment with tissue plasminogen activator in acute myocardial
infarction. Am J Cardiol 1990; 66: 261-6.
14. Schofer J, Büttner J, Geng G et al. Prehospital thrombolysis in acute myocardial infarction.
Am J Cardiol 1990; 66: 1429-33.
15. McAleer B, Ruane B, Burke E et al. Prehospital thrombolysis in a rural community: short and
long-term survival. Cardiovasc Drugs Ther 1992; 6: 369-72.
16. Rozenman Y, Gotsman MS, Weiss AT et al. Early intravenous thrombolysis in acute
myocardial infarction: the Jerusalem experience. Int J Cardiol 1995; 49(suppl): S21-8.
17. Linderer T, Schroder R, Arntz R et al. Prehospital thromblysis: beneficical effects of very early
treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993; 22: 1304-10.
18. Coccolini S, Berti G, Bosi S et al. Prehospital thrombolysis in rural emergency room and
subsequent transport to a coronary care unit: ravenna myocardial infarction (RaMI) trial. Int J
Cardiol 1995; 49(suppl): S47-58.
19. French J, Williams B, Hart H et al. Management of acute myocardial infarction in Auckland.
NZ Med J 1996; 109: 248-51.
20. Lambrew CT, Bowlby LJ, Rogers WJ et al. Factors influencing the time to thrombolysis in
acute myocardial infarction. Time to Thrombolysis Substudy of the National Registry of
Myocardial Infarction-1. Arch Intern Med 1997; 157: 2577-82.
21. Hirvonen TP, Halinen MO, Kala RA, Olkinuora JT. Delays in thrombolytic therapy for
acute myocardial infarction in Finland. Results of a national thrombolytic therapy delay
study. Finnish Hospitals’ Thrombolysis Survey Group. Eur Heart J 1998; 19: 885-92.
22. Weaver WD, Eisenberg MS, Martin JS et al. Myocardial infarction triage project - phase 1.
Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am
Coll Cardiol 1990; 15:925-31.
23. Palmer DJ, Cox KL, Dear K, Leitch JW. Factors associated with delay in giving thrombolytic
therapy after arriving at hospital. Med J Aust 1998; 168: 111-4.
24. Rawles J, Sinclair C, Jennings K et al. Call to needle times after acute myocardial infarction in urban
and rural areas in northeast Scotland: prospective observational study. BMJ 1998; 317: 576-8.
25. Rawles JM. The magnitude of benefit from earlier thrombolysis in acute myocardial
infarction. New evidence from the Grampian region early anistreplase trial (GREAT). BMJ
1996; 312: 212-5.
200 New Zealand Medical Journal 11 May 2001
Adverse Events Regional Feasibility Study: methodological results
Peter Davis, Professor, Department of Public Health and General Practice, Christchurch School of Medicine,
University of Otago, Christchurch; Roy Lay-Yee, Analyst, Department of Community Health, School of Medicine,
University of Auckland, Auckland; Stephan Schug, Associate Professor, Department of Anaesthesia, University
of Western Australia, Perth; Robin Briant, Clinical Director, Department of Community Health, School of Medicine;
Alastair Scott, Professor, Department of Statistics; Sandra Johnson, Project Manager; Wendy Bingley, Data
Manager, Department of Community Health, School of Medicine, University of Auckland, Auckland.
Abstract
Aims. To assess the feasibility of research into the
occurrence, causation and prevention of adverse events
(AEs) in New Zealand public hospitals.
Methods. A two-stage retrospective review was carried out
on 1575 medical records selected by systematic list sample
from admissions for 1995 in three public hospitals in the
Auckland region. Following initial screening, medical
records were subject to structured implicit review using a
standardised protocol. Feasibility measures, using
international benchmarks where possible, were: adequacy
of sample selection; completeness of medical records;
reliability and validity of screener and reviewer judgements;
internal consistency and face validity of AE determination
and preventability assessment.
Results. The sample selection procedure was effective,
although nearly 10% of records could not be secured.
Information in medical records was sufficient for the
identification and analysis of AEs. Adequate levels of
agreement were achieved for screener and reviewer
judgements, with kappa scores ranging between 0.302 and
0.622 and positive predictive values between 50.0% and
89.7%. The criteria for AE determination showed internal
consistency and face validity, as did those for
preventability.
Conclusions. Research into the occurrence, causation and
prevention of AEs in New Zealand health care settings is
methodologically feasible and meets international
benchmark standards.
NZ Med J 2001; 114: 200-2
In New Zealand the question of patient safety has, to date,
been the subject of relatively little systematic research. One
of the first studies to use a standardised, epidemiological
approach was a survey of adverse drug events among over
9000 admissions to Dunedin hospital in the early 1970s.1
While useful research since that time has been carried out
on surgical audit2 and anaesthetic error,3 and while the
Ministry of Health has published some standardised
information across New Zealand hospitals,4 no generic,
epidemiological data on adverse events (AEs) has been
published in this country. The absence of such data has been
recognised as an obstacle to developing proposals for the
regulation of safety in health and disability.5
A major scientific stimulus to rigorous epidemiological
research on patient safety has been the development of
standardised procedures for the assessment of AEs using
medical records. It was not until the Harvard Medical
Practice Study (HMPS) that a measurably reliable, valid and
generic definition of AEs was first established across a wide
range of clinical settings.6 This approach has been replicated
in the Quality in Australian Health Care Study (QAHCS).7
The object of this study was to test the feasibility of
applying a standardised protocol to the analysis of medical
records with a view to determining the occurrence, causation
and prevention of AEs in New Zealand public hospitals.
Methods
Sampling and data collection. Three major public hospitals were
selected for study in the Auckland region. The survey population was
defined as all patient admissions to these hospitals for calendar year 1995
(excluding day and psychiatric cases). The sampling frame for each
hospital was a list of all eligible admissions. New Zealand Health
Information Service (NZHIS) selected a systematic list sample of 525
admissions from each hospital, with cases ordered by admission date.
Each selected case signalled an index admission. To be included in the
study an AE had to be related to, or occur during, the index admission.
Standard hospital inpatient information for each sampled admission
was provided by NZHIS. This included admissions information (dates of
admission and discharge, admission type and source), socio-demographic
data (age, gender, ethnicity, domicile code), and clinical data (ICD9 and
AN-DRG3.1 diagnostic classifications).
The core data collection procedure was a two-stage retrospective
review of medical records for selected cases using the Review Form 1
(RF1) and Review Form 2 (RF2), both closely modelled on the
comparable instruments in the American and Australian studies.6,7  The
first stage was the RF1 screen undertaken by Registered Nurses (RNs).
The purpose of this stage was to ascertain if the hospitalisation in
question - the index admission - met any of eighteen screening criteria
selected as potentially indicative of an AE.8 The second stage undertaken
by Medical Officers (MOs) used the RF2, an instrument relying on
structured implicit review (that is, the guided exercise of professional
judgement), and was designed to determine the presence and context of
any AE. In two of the three hospitals an Expert Reviewer (ER)
administered “blind” the full cycle of data collection on a one-in-ten sub-
sample.
Definitions.8 An AE was operationally defined as (a) an unintended
injury or unintended complication, (b) resulting in temporary or
permanent disability, including increased length of stay and/or financial
loss to the patient, (c) that was caused by health care management rather
than the underlying disease process. A key part of AE determination was
the assessment of the extent to which an identified injury resulting in
disability was caused by health care management. In order to assist
reviewers to make this judgement they were guided through a series of
seven evaluation questions.
Preventability of an AE was assessed as an error in health care
management due to failure to follow accepted practice at an individual or
system level.  In order to assist reviewers in making a judgement about
the preventability of AEs they were required to work through ten
evaluation questions.
Evaluation of feasibility. (1) Adequacy of sampling – comprehensive
sample frame and “success rate” in accessing records. (2) Completeness of
records – information available for data collection. (3) Reliability – kappa
and positive and negative predictive values (MO as criterion). (4) Validity
– kappa and positive and negative predictive values (ER as criterion). (5)
Internal consistency and face validity – assessment of AE determination
and level of preventability against individual items using positive and
negative predictive values (analysis of AE status against discharge mode,
ICD external cause code and length of stay, was also carried out, but
these results are not reported in full).
Where possible, benchmark comparisons will be made with the
corresponding data drawn from QAHCS.8
Results
Adequacy of sampling. Of the 246 sampled records that
could not be screened, 30.1% could not be retrieved, 24.4%
had inadequate documentation, and 45.5%, mainly day stay,
were incorrectly included in the sample by NZHIS. There
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were also three records screened criteria positive but not
available for further review. Excluding the mis-sampled
admissions, the success rate was 90.8%.
Completeness of medical records (Table 1). For the first
stage of the review procedure, the RN screen, the available
information was judged to be sufficient to complete all
aspects of the RF1 in nearly 95% of all sampled records. For
the second stage, the MO review, the available information
was deemed sufficient to complete all aspects of the RF2 for
nearly 85% of all cases classed as AEs, and in the remainder
was adequate to determine AE occurrence.
Table 1. Adequacy of medical records.
Medical Record Items RN* Screening (RF1†): MO‡ Reviewing (RF2§):
Percentage of screened  Percentage of AE
admissions admissions
Initial medical assessment 99.5 % 96.5 %
(n=1326) (n=142)
If applicable:
Medical progress notes 98.7% 91.5%
Nursing progress notes 99.4% 97.9%
Procedure documentation 99.2% 97.2%
Pathology reports 98.6% 98.6%
Discharge summary 96.3% 94.4%
All above items adequate 94.1% 84.5%
* Registered Nurse. † Review Form 1. ‡ Medical Officer. § Review Form 2.
 Reliability and Validity (Table 2). Reliability showed only
moderate results. While agreement on criteria presence was
high (89.7%), the positive predictive value for AE presence
was a little over 50%. There was a similar pattern with
validity. There was a low level of agreement for screeners on
AE presence. However, positive predictive value and kappa
scores were acceptable for criteria presence and AE
determination. The small number of cases for AE
determination should be noted.
Table 2. Reliability and validity of screener and reviewer judgements.
Kappa Percent Positive Negative
agreement predictive predictive
value value
Reliability
RN*/MO†: criteria presence‡ (n=553) - 89.7% 89.7% -
RN/MO: AE presence (n=548) 0.344 74.8% 51.4% 83.0%
Validity
RN/ER§: criteria presence (n=74) 0.465 74.3% 71.4% 76.1%
RN/ER: AE presence (n=72) 0.302 86.1% 50.0% 89.4%
MO/ER: AE determination (n=28) 0.622 85.7% 62.5% 95.0%
* Registered Nurse. † Medical Officer. ‡ Only cases screened positive by RNs were
further reviewed by MOs; thus kappa and negative predictive value are not
applicable. §Expert Reviewer.
AE Determination (Table 3 and Figure 1). The results of
reviewer responses on AE determination are presented.  The
first question, whether there was a note in the record suggestive
of the causal role of health care management, was strongly
predictive of an AE (positive predictive value=92.7%). In the
case of the second question – a note predictive of injury – the
relationship was weak. The assessment of the timing of events
was the only other item that was strongly predictive of a
reviewer’s attribution of an AE. The remaining questions
showed a moderate tendency to be predictive of an AE.
Following these seven evaluation questions reviewers were
then required to make an assessment of the degree to which the
outcome was ‘caused’ by health care management. The results
of this exercise are outlined in Figure 1. For nearly half of all
cases with both injury and disability or longer hospital stay
there was virtually no evidence of health care management
causation in the opinion of the reviewer. These were excluded
from further analysis. The full protocol - RF2 - was
administered to the remaining 142 cases. It is notable, however,
that only 70 of these showed moderate, strong or virtually
certain evidence of health care management causation.
Table 3. Adverse event status by evaluation category: percent
agreement and predictive value.
Evaluation Category Adverse Event Status (n=235)
[POSITIVE/negative] [Present (n=142)/ Absent]
Percent Positive Negative
agreement predictive value predictive value
Q. Is there a note in the medical record which indicates or suggests that health care
management caused the injury?
YES/no 79.6% 92.7% 67.5%
Q. Is there a note in the medical record which predicts the possibility of an injury from
the patient’s disease?
NO/yes 56.5% 65.2% 44.0%
Q. Does the timing of events suggest that the injury was related to the treatment?
LIKELY/possible, unlikely 76.8% 83.6% 67.7%
Q. Are there other reasonable explanations for the cause of the injury?
FEW/some, many 63.5% 75.9% 51.8%
Q. Was there an opportunity prior to the occurrence of the injury for intervention
which might have prevented it?
YES/possibly,no 52.0% 75.9% 43.6%
Q. Is there recognition that the intervention in question causes this kind of injury?
WIDELY/recognised by other
 specialists,no 62.3% 81.1% 32.1%
Q. Did the adverse event respond to new management to neutralise or modify the
effects of former management?
CONVINCING/suggestive,no 60.5% 75.2% 37.3%
Assessment of preventability (Table 4). The results of
reviewer responses on assessment of preventability are presented.
Figure 1. Assessing health care management causation.
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Whether there was consensus about diagnosis and therapy had
little bearing on their judgement of preventability (positive
predictive value=46.0%). Complexity, co-morbidity, degree of
emergency, potential benefit, chance of benefit, and risk of an AE
were other questions with little predictive value. By contrast,
appropriateness of management, deviation of management from
the accepted norm, and reflection on repetition were questions
that were more predictive of reviewers’ judgements of high
preventability.
Table 4. – High preventability* of adverse events by evaluation
category: percent agreement and predictive value.
Evaluation Category High Preventability of Adverse Events  (n=142)
[POSITIVE/negative] [Present (n=55)/ Absent]
Percent Positive Negative
agreement predictive value predictive value
Q. Is there consensus about diagnosis and therapy regarding this case?
GREAT DEAL/some,
very little 56.4% 46.0% 73.6%
Q. How complex was the case?
UNCOMPLICATED/moderate,
very 58.2% 45.8% 64.5%
Q. Was the management in question appropriate?
NOT, POSSIBLY/probably,
definitely 75.0% 75.7% 74.8%
Q. What was the co-morbidity of the case in which the adverse event occurred?
NONE/moderate, very ill 51.8% 38.2% 60.5%
Q. What was the degree of deviation of management from the accepted norm?
SEVERE, MODERATE/little 69.8% 67.6% 70.6%
Q. What was the degree of emergency in management of the case prior to the occurrence
of the adverse event?
NONE/moderate, critical 58.6% 46.7% 64.2%
Q. What potential benefit was associated with the management?
MINOR/major, life-saving 52.8% 23.8% 58.5%
Q. What was the chance of benefit associated with the management?
HIGH/moderate, low 51.2% 38.8% 65.0%
Q. What was the risk of an adverse event related to the management?
HIGH, MODERATE/low 50.8% 41.3% 63.2%
Q. On reflection, would a reasonable doctor or health professional do this again?
NO,PROBABLY NOT/
probably,definitely 72.5% 72.7% 72.4%
*  Preventability judged to be more likely than not.
Discussion
The primary objective of this study was to assess the
feasibility of conducting research into the occurrence,
causation and prevention of AEs .
In methodological terms the feasibility study was able, in the
first instance, to establish the adequacy of the sample frame and
the effectiveness of the sampling procedure. In QAHCS,7 for
example, the sample frame had to be constructed for each
hospital. Through NZHIS we were able to draw samples
centrally. The success rate - that is, the proportion of sampled
records which was screened – was, however, relatively low;
90.8% compared with the Australian rate of 96.8%.8
The level of the information available appeared to be
adequate, and comparable to international results. Thus, the
standards of medical documentation were sufficient to permit
almost universal completion of the RF1. In the case of the
RF2, while the determination of AE status was possible in
virtually all cases, at least one data item was missing in a sixth
of completed RF2s. These results are comparable to those
achieved in the Australian study.8 The quality of the
assessment process – that is, the level of agreement on the
screening and reviewing tasks - was adequate when compared
to the results from QAHCS.
More important to the validity of the study was the process of
AE determination. In QAHCS and HMPS two MO reviewers
were used, with arbitration in case of disagreement. Despite this,
the overall level of agreement in these studies was low.9 This
confirms the conclusion of one authority that physician
agreement on the quality of care is often only slightly better than
chance.10 Furthermore, research suggests that discussion between
reviewers does not actually improve the reliability of peer review
of hospital quality.11 In this investigation, as in the more recent
Utah and Colorado studies (UTCOS), only a single MO was
used, with ‘blind’ expert review of a 10% sub-sample.  The
positive predictive value for agreement between MO reviewers
and ERs - admittedly on a small sample - was 62.5%
(kappa=0.622). This equates to the level of agreement achieved
between MOs in QAHCS (kappa=0.55)8 and between reviewers
in a reliability study of a sub-sample in UTCOS (kappa=0.4).12
The study broke relatively new ground in attempting to
go beyond conventional measures of internal validity. Thus
it was possible to use the evaluation items in the assessment
of AE status and of preventability to establish the internal
consistency and face validity of reviewer judgements. For
example, of the records assessed for AE status and which had
a note indicating that health care management was causative,
over 90% were judged by reviewers to be AEs. Similarly,
where the reviewer deemed management inappropriate, a
high level of preventability was a likely assessment.
In a separate exercise not reported here, internal consistency
was also assessed against routinely-collected hospital
information. In this case, however, results did not prove to be
useful. In particular, external cause codes signalling medical
misadventure had low sensitivity, identifying only a quarter of
AEs, although length of stay was more predictive (a greater
than average stay was associated with half all AEs).
In conclusion, this study was designed to test at a regional level
the feasibility of carrying out research on the detection and
analysis of AEs. The investigation has demonstrated sufficient
levels of performance in methodological terms, as judged by
international benchmark standards for work of this kind.
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Abstract
Aims. To identify substantive findings of potential clinical
and managerial significance from a regional feasibility
study of adverse events (AEs).
Methods. A standardised protocol using structured
implicit review was applied to 142 AEs generated in an
audit study of three public hospitals in the Auckland region
for admissions in 1995. Areas of potential significance
addressed were: timing, location and impact of AEs;
preventability; and clinical context and predictability.
Results. 142 cases were identified as AEs (10.7% of 1326
screened records). In 102 cases, 7.7% of all screened records,
it was considered to be more likely than not that health care
management contributed to the AE. About half the reported
AEs occurred before the index admission, the majority
NZ Med J 2001; 114: 203-5
outside hospital. Over half of all events resulted in disability
that was resolved within a month. An average 6.7 extra days
stay in hospital were attributable to AEs. For 60% of AEs
the evidence for preventability was either low or non-
existent. Areas of potential prevention were predominantly
educational. Over half of all AEs occurred in a surgical
context. Medical AEs were more likely to have occurred
outside hospital, to be drug-related, to be associated with an
acute admission, to be classified as highly preventable, and to
have a greater impact on hospital stay.
Conclusions. Although the data generated by a feasibility
study must be treated with caution, the pattern of results is
consistent with comparable Australian findings and is of
potential clinical and managerial significance.
The subject of patient safety, and the quality of health care,
has gained increasing momentum. Although it has been over
a decade since the publication of the first authoritative
estimates of adverse events (AEs) in the Harvard Medical
Practice Study (HMPS),1 within the last eighteen months
there has been a report on patient safety from the Institute
of Medicine2 and an  issue of the British Medical Journal
devoted to medical error.3 Other journals have also
canvassed the question4-6 and studies on AEs and medical
error have been published in other developed countries.7,8
The matter has also gained attention in the United
Kingdom because of highly-publicised incidents, such as the
Bristol affair. 9
Interest in patient safety has also been evident in Australia,
with some of the earliest work published on anaesthesia-
related mortality.10 The first broad-based and representative
investigation using internationally standardised and clinically
generic procedures of AE determination was the Quality in
Australian Health Care Study (QAHCS).11
In New Zealand the question of patient safety has, to date,
been little researched. The methodological results from a
feasibility study designed to test the application of such
standardised epidemiological techniques in the New Zealand
setting is reported in the preceding article.12 This article
presents some key substantive findings from the feasibility
study that may be of clinical and managerial significance.
These relate to the timing, location and impact of AEs, their
preventability, and their clinical context and predictability.
Methods
Sampling and data collection. Three major public hospitals were
selected for study in the Auckland region. The survey population was
defined as all patient admissions to these hospitals for calendar year 1995
(excluding day and psychiatric cases). Fuller details on sampling are
provided in the preceding paper.12
Standard hospital inpatient information for each sampled admission
was provided by NZHIS. This included admissions information (dates of
admission and discharge, admission type and source), socio-demographic
data (age, gender, ethnicity, domicile code), and clinical data (ICD9 and
AN-DRG3.1 diagnostic classifications).
The core data collection procedure of the study was a two-stage
retrospective review of medical records for selected cases using the
Review Form 1 (RF1) and Review Form 2 (RF2), both closely modelled
on the comparable instruments in the American and Australian studies. In
two of the three hospitals an Expert Reviewer (ER) administered “blind”
the full cycle of data collection on a one-in-ten sub-sample. Fuller details
on data collection are provided in the preceding paper.12
Definitions.11 An AE was defined as (a) an unintended injury or
unintended complication, (b) resulting in temporary or permanent
disability, including increased length of stay and/or financial loss to the
patient, (c) that was caused by health care management rather than the
underlying disease process.
Disability was defined as: temporary, lasting up to a year, or permanent
impairment of function; death; or prolonged hospital stay even in the
absence of impairment.
Preventability of an AE was assessed as an error in health care
management due to failure to follow accepted practice at an individual or
system level.
Potential for prevention of recurrence of particular AEs was assessed
by MO reviewers identifying broad ‘areas of effort’.
Because of the small size of the sample – 142 AEs – no formal
statistical analysis is used in this paper. Any evaluative judgements applied
to patterns in the data, therefore, while they may be suggestive of clinical
or managerial relevance, do not imply statistical significance.
Results
Frequency. Of 1575 medical records sampled, and allowing
for missing and excluded data, 515 were screened criteria
positive and went on to medical review.12 Of these, 142 cases
were identified as AEs (10.7% of all screened records). In
102 cases, 7.7% of all screened records, it was considered to
be more likely than not that health care management
contributed to the AE.
Timing, location and impact. Information on the timing,
location and impact of adverse events is presented in Table
1. Looking at all AEs, about a half occurred before the
sampled (index) admission and an extra 6.7 days was added
to hospital stay. A third of all AEs took place outside a public
hospital (mostly in ambulatory settings) and had a greater
than average effect in lengthening hospital stay. Over half of
all events occurring before the index admission took place
outside a public hospital. AEs occurring inside hospital and
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during the index admission had least impact on length of
hospital stay.
Table 1. Distribution of AEs – by location and timing of occurrence.
Location Before During All AEs
index admission index admission
Percent Mean percent Mean Percent Mean
ABD* ABD ABD
Inside 42.3% 8.9 100% 4.5 68.3% 6.1
Hospital (n=97)
Outside 57.7% 8.0 - - 31.7% 8.0
Hospital (n=45)
100% 100%
All AEs 54.9% 8.4 45.1% 4.5 100% 6.7
(n=78) (n=64) (n=142)
*Attributable bed days in the study hospital, spent over one or more admissions
associated with an AE.
The effect of AEs on the health status of patients is assessed
in Table 2. For most patients - more than half - any
disability suffered as a result of an AE resolved within a
month. The impact on hospital workload - as measured by
attributable bed days (ABD) - increased noticeably for more
severe and more long-term disability.
Table 2. Impact of AEs – disability status by hospital stay.
Disability Percent Mean ABD*
(n=142)
Minimal < 1 month† 56.3% 4.1
Moderate 1-12 months 20.4% 11.0
Permanent ≤50% 3.5% 23.4
Permanent >50% 2.1% 27.5
Death 6.3% 3.9
Unable to tell 11.3% 4.3
All AEs 100% 6.7
*Attributable bed days in the study hospital, spent over one or more admissions
associated with an AE. †Period of disability.
Preventability. Information on reviewer assessments of the
preventability of AEs is presented in Table 3. In a third of
cases the reviewers judged there to be virtually no evidence
of preventability. For another third of cases the evidence was
weak to equivocal, while for the remainder the judgement of
preventability was much more definitive.
Table 3. AEs – Attribution of preventability.
Preventability* Frequency Percent
1.  Virtually no evidence 45 31.7%
2.  Slight to modest evidence 27 19.0%
3.  Close call, <50:50 14 9.9%
4.  Close call, >50:50 25 17.6%
5.  Moderate/strong evidence 22 15.5%
6.  Virtually certain evidence 8 5.6%
Missing 1 0.7%
All AEs 142 100%
*Categories 4, 5 and 6 are classified as ‘high’ preventability.
In Table 4, ‘areas of effort’  - that is, the potential for the
prevention of recurrence - are considered alongside impact
and preventability. The largest category identified by
reviewers was improved education, followed by improved
resources, quality assurance, communication, and systems
reorganisation. The area with the greatest adverse impact
was poor quality assurance, while the area with the highest
level of preventability was systems error. Improved
education was the largest category for prevention, but its
profile was an average one for both impact and
preventability.
Table 4. Prevention of recurrence – areas of effort by impact and
preventability.
Area for Attention* % All AEs %Perm. Mean % High
disability ABD† preventability
/death
Education 41.6% (59) 13.6% 6.9 61.0%
Resources 10.6% (15) 13.3% 6.7 66.7%
Quality assurance 9.2% (13) 30.8% 10.2 61.5%
Communication 9.2% (13) 23.1% 7.5 61.5%
System 6.3% (9) 11.1% 6.5 88.9%
Other 14.8% (21) 4.8% 9.9 66.7%
All AEs 100% 12.0% 6.7 38.7%
(n=142) (n=17) (n=55)
*More than one area could be chosen. †Attributable bed days in the study
hospital, spent over one or more admissions associated with an AE.
Clinical context and predictability. Reviewers classified
AEs according to specialty and area of clinical application.
This information, together with other features of clinical
context, is presented in Table 5. Overall, AEs were
reasonably evenly distributed across medicine and surgery.
Operative and drug-related incidents were the commonest
clinical areas involved. The former were more characteristic
of surgery and of AEs internal to hospital, the latter of
medicine and of AEs external to hospital. Events classified in
medicine were also more likely – when compared
(conservatively) to AEs overall - to occur outside hospital, to
be associated with an acute admission, and to have co-
morbidity present.
Table 5. Specialty and clinical area.
AEs Occurred All AEs Specialty
Inside Outside Surgery* Medicine† Other‡
hospital hospital
68.3% 31.7% 100% 51.4% 44.4% 4.2%
(n=97) (n=45) (n=142) (n=73) (n=63) (n=6)
Clinical Area§
Operative 33.3% 9.6% 25.5% (40) 47.0% 1.4%
Drug 12.4% 36.5% 20.4% (32) 7.2% 37.7%
System 16.2% 17.3% 16.5% (26) 15.7% 17.4%
Other|| 38.1% 36.5% 37.6% (59) 30.1% 43.5%
Total mentions 100% 100% 100% (157) 100% 100%
% of AEs: Outside Hospital 31.7% 12.3% 50.8%
% of AEs: Transfer admission 7.0% 8.2% 4.8%
% of AEs: Acute admission 68.3% 48.0% 92.1%
% of AEs: Co-morbidity present 47.2% 39.7% 55.6%
*Includes all surgical specialties plus anaesthesiology and obstetrics. †Includes all
medical specialties plus psychiatry and paediatrics. ‡Includes dentistry/oral
surgery, dietary, hospital physical plant, midwifery, nursing, pharmacy,
occupational therapy, physiotherapy, podiatry, transportation support services,
speech/language therapy. §An AE in a particular clinical area could be
additionally classified as ‘system’. ||Therapy, procedures, diagnosis, falls,
fractures, obstetrics, neonatal, or anaesthesia; each area contained <10% of
mentions.
The impact and preventability of AEs by specialty and
clinical area are shown in Table 6. Incidents classified in
medicine tended to have a greater effect on hospital stay and
were seen as more highly preventable than surgical AEs.
Drug-related events had a greater impact on bed days, and
systems errors were seen to be more preventable.
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Table 6. Impact and preventability - by specialty and clinical area.
% permanent Mean ABD* % High
disability/death Preventability
All AEs (n=142) 12.0% (n=17) 6.7 38.7% (n=55)
Specialty
Surgery (n=73) 8.2% 6.0 24.7%
Medicine (n=63) 14.3% 7.7 56.5%
Other (n=6) 33.3% 5.6 33.3%
Clinical Area†
Operative (n=40) 7.5% 5.7 20.0%
Drug-Related (n=32) 15.6% 8.4 43.8%
System (n=26) 19.2% 7.0 76.0%
Other (n=59) 10.2% 6.4 42.2%
*Attributable bed days in the study hospital, spent over one or more admissions
associated with an AE. †An AE in a particular clinical area could be additionally
classified as ‘system’.
Discussion
Many of the key substantive findings outlined in this paper
are not only of potential clinical and managerial significance;
they also add to confidence in the overall study   because of
their consistency with the comparable Australian results. For
example, about half of AEs occurred before admission, a
high proportion of events were regarded as not preventable,
the great majority of events resulted in disability that was
temporary, but resulted in an average of just under seven
extra days hospital stay. These are all findings of intrinsic
clinical and policy interest, but they are also of an order of
magnitude comparable with results generated in QAHCS.11
 There are other findings reported here that were
relatively unanticipated and that invite further attention. For
example, a third of all AEs occurred outside the hospital
setting. Similarly, and related to this, there appeared to be a
pattern of drug-related events, many of which occurred
outside hospital. Furthermore, routinely-collected hospital
data showed some predictive power, with over 90% of
medical AEs and about half of surgical AEs associated with
an acute admission.
These two findings - the importance of adverse drug
events (ADEs) and the possibilities of administrative data  -
provide examples, respectively, of potential clinical and
managerial significance. They have been reported elsewhere
in the literature and underline the potential for further
development in these areas. Thus, Bates et al evaluated
fifteen screening criteria for their sensitivity and specificity
in predicting AEs, preventable AEs, and serious AEs.13
Although no set of administrative data was particularly
sensitive - that is, able to predict a high percentage of AEs -
using such data was much less costly than other methods of
detection. Similarly with ADEs; a high proportion are
preventable.14 Data of this kind in turn can lead to a search
for causes.15
In conclusion, this feasibility study has generated
substantive results that not only engender confidence in the
methodology - being generally consistent with findings
reported from other studies - but are also of potential
clinical and managerial application.
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Insurers to use gene test for Huntington’s disease
The United Kingdom has become the first country to give official approval for the use of results from genetic tests for Huntington’s disease for insurance
purposes.
An advisory committee to the government – the Genetics and Insurance Committee – last week reported that the reliability and relevance of two
genetic tests for Huntington’s disease are sufficient for insurance companies to use the results when assessing applications for life insurance.
The approval was given in response to an application from the professional body representing the insurance industry, the Association of British
Insurers, to use information from such testing.
Professor John Durant, chairman of the Genetics and Insurance Committee and professor of the public understanding of science, Imperial College,
London, explained that the recommendation gives official endorsement to what is already current practice: “The evidence we reviewed demonstrated that
the two tests for Huntington’s gene are reliable and that an abnormal result is associated with significant clinical effects and with an increased probability
of a claim on a life insurance policy.”
The decision does not mean that individuals will be required to have a genetic test for Huntington’s disease before obtaining insurance. But people who
have already been tested – usually because the condition has occurred in a family member – may be asked for the result by insurance companies.
Susan Mayer. BMJ 2000; 321: 977.
206 New Zealand Medical Journal 11 May 2001
The community services card: does it make a difference to pharmaceutical
utilisation?
Frances Sutton, consultant, Wellington; Peter Crampton, Senior Lecturer, Department of Public Health, Wellington
School of Medicine and Health Services Research Centre, Wellington.
The plan to introduce community services cards (CSCs) and
high use health cards (HUHCs) was first announced in the
July 1991 National Government Budget along with planned
changes to the New Zealand health system.1 From 1/2/1992
low income families and some chronically ill people became
eligible for CSCs and HUHCs respectively. Possession of a
card entitled the holder to a higher rate of subsidy for GP
consultations and prescriptions, and to lower user charges
for certain hospital and secondary services. The overall aim
of the CSC was to target more effectively state assistance for
certain primary care services.2 The estimated CSC holding
rate for the year ended June 1999 was 39.3%.3
As the principal tool aimed at reducing financial barriers
to access for primary care services, the CSC has been
criticised on several counts. Problems such as low uptake,
the ‘poverty trap’ effect around the eligibility threshold (the
abrupt cut-off for CSC eligibility creates a ‘poverty trap’ at
the low end of the non-eligible population), lack of indexing
of subsidy levels to take account of inflation, as well as the
actual subsidy level (which typically results in a part-charge
to the patient), have meant that significant barriers to access
(ie, part-charges) have persisted for many families.2,4-6
The aim of this paper is to assess whether the targeted
subsidy regime has benefited CSC holders by comparing, at
a national level, average utilisation and subsidy cost of
prescription items for CSC holders and non-holders.
Utilisation is defined in terms of prescription items
processed by Health Benefits Limited (HBL), and costs are
defined by government-funded (ie, excluding user charges)
costs of these items.
Methods
Data and methods for calculating the utilisation rates are described
elsewhere.3
Data sources. Data were from the following sources: IMS Health (a
market research company) and HBL (prescribing data); Statistics New
Zealand (population projections); and Work and Income New Zealand
(WINZ) (CSC population data). IMS provided from their Medical Index
numbers of prescription items by age group, sex, and CSC/HUHC status,
collected from a stratified sample of 300 general practitioners (GPs). The
stratification was based on the four Health Funding Authority (HFA)
regions. The GPs in the sample reported for seven consecutive days. The
IMS panel did not consist of the same doctors for the whole year. IMS
bulked up the sample so that the number of prescription items
represented New Zealand GP usage. The IMS data counted each repeat
prescription as one item, and in this respect matched HBL data. Unlike
HBL data, the IMS data were intended to capture all prescription items,
unsubsidised as well as subsidised.
Calculation of IMS-derived utilisation rates. The 10% of prescription
items with missing values of the categorical variables (eg, age, sex) were
distributed over categories without missing values using proportionality
assumptions. The IMS and population data were used to compute
utilisation rates (prescription items per head per year by age, sex, CSC and
HUHC). Denominator populations for the utilisation rates were estimated
using Statistics New Zealand population projections at 30/6/1998 and 30/
6/1999, CSC population data from WINZ, information on HUHC-
holding from HBL, and HUHC prevalence rates (probability of HUHC-
holding, by age, sex and CSC estimated from a sample of 1 million patients
from practice registers of primary care organisations participating in an
HFA pilot project on capitation funding for primary care).
Adjustments had to be made to the utilisation rates for some of the
elderly population. First, rates for age 85+ years appeared inconsistent
with each other and with younger age groups, probably because of small
sample size and denominator problems. The latter arose because a
material proportion of the population aged 85+ years is resident in a
geriatric hospital, and should be (but was not) excluded from the
population denominators. IMS stated that such residents were not
included in their survey (rest-home residents were included). For males
and non-HUHC females, utilisation rates derived from the IMS data
were replaced with estimates defined thus:
[Rate for age 85+] = 1.3 x [Rate for age 75-84].
The factor of 1.3, though somewhat arbitrary, was based on the
following evidence: 1) the relationship in the IMS data between rates for
ages 65-74 and 75-84 years; 2) the relationship of discharge rates for ages
75-84 and 85+ years for discharges from publicly-funded hospitals.
Secondly, for HUHC females aged 75-84 and 85+ years, the utilisation
rates calculated from the IMS data were implausibly low. These two rates
were replaced with the rate for HUHC females of age 65-74 years. There
was no alternative to an essentially arbitrary estimate.
Utilisation rates for the whole population by age, sex and CSC were
obtained by assuming that age- and sex-specific utilisation rates for
HUHC holders were  the same regardless of CSC status.
Utilisation rates for HBL-processed items and subsidy cost per
head per year. Some items for non-CSC/HUHC adults are not
processed by HBL, as they cost less than the $15 prescription charge.
The IMS data, however, include such items. The first step of the
method, therefore, involved reducing by 20% IMS-derived numbers of
items per head for non-CSC/HUHC adults. This percentage is the
estimated proportion of items for this population that were dispensed,
but not processed by HBL. The estimate is based on the assumption
that for adults, prescriptions with a gross cost under $15 as a proportion
of all prescriptions dispensed is the same for CSC holders and non-
holders. Gross cost is defined as the subsidy plus the prescription charge
(which excludes the manufacturers’ surcharge). This step resulted in
IMS-derived utilisation rates by age, sex and CSC/HUHC status,
reduced as described for non-CSC/HUHC adults.
The second step involved scaling these rates to match numbers of
items from HBL. The scaling was such that when the scaled rates
Abstract
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CSC-holders was lower than for non-holders; the reverse
was true for adults.
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utilisation rates than non-holders at a national level (but
not necessarily at a local level). If non-uptake of cards and
health status were taken into account, however, it is
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optimal amongst those most in need of services. Analyses
are urgently required to examine prescribing patterns at a
regional level.
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(Table 1) were applied to national populations the result was national
totals (by card and broad age group) of HBL-processed item numbers.
This step should eliminate most or all bias arising from items that are
prescribed but not dispensed. The final step yielded rates of subsidy
cost per head (Table 2). These rates were obtained by calculating
subsidy cost per item from HBL (Table 3), and applying these unit
costs to the utilisation rates of the previous step. The HBL data
permitted no sex disaggregation of unit cost, and only limited age
disaggregation.
Table 1. Number of HBL-processed items per head and ratio of
rates (CSC / non-CSC) for the year ended June 1999.
Sex Age Rate Rate Ratio
group CSC No CSC
F 0 11.4 7.2 1.6
1-4 9.9 6.9 1.4
5-14 3.2 1.7 1.9
15-24 11.2 2.8 3.9
25-44 15.3 3.6 4.3
45-64 22.1 7.8 2.8
65-74 30.9 11.8 2.6
75-84 33.8 17.3 2.0
85+ 43.3 23.3 1.9
M 0 14.4 7.9 1.8
1-4 9.9 7.5 1.3
5-14 3.1 1.5 2.0
15-24 3.0 1.4 2.2
25-44 5.6 2.4 2.4
45-64 17.3 5.4 3.2
65-74 27.2 11.0 2.5
75-84 31.0 19.3 1.6
85+ 40.9 26.6 1.5
NZ* 13.3 5.1 2.6
* Age/sex standardised using NZ 1998/99 population.
Table 2. Cost ($ ex GST) per head, and ratio of rates (CSC / non-
CSC) for the year ended June 1999.
Sex Age Rate Rate Ratio
group CSC No CSC
F 0 108 64 1.7
1-4 94 62 1.5
5-14 45 20 2.2
15-24 176 47 3.7
25-44 247 65 3.8
45-64 359 141 2.5
65-74 502 216 2.3
75-84 551 316 1.7
85+ 710 429 1.7
M 0 136 70 1.9
1-4 94 67 1.4
5-14 43 18 2.4
15-24 47 23 2.0
25-44 90 43 2.1
45-64 280 98 2.9
65-74 442 201 2.2
75-84 505 353 1.4
85+ 674 488 1.4
NZ* 209 86 2.4
* Age/sex standardised using NZ 1998/99 population.
Table 3. Cost ($ ex GST) per item, and ratio of unit costs (CSC /
non-CSC) for the year ended June 1999.
Age group CSC No CSC Ratio
0, 1-4 9.5 8.9 1.1
5-14 13.8 11.7 1.2
15-24 15.7 16.6 0.9
25-44, 45-64 16.1 18.1 0.9
65-74, 75-84 16.2 18.1 0.9
85+ 16.4 18.2 0.9
NZ* 15.2 16.2 0.9
* Age/sex standardised using NZ 1998/99 population.
Results
For both sexes, and for all age groups, CSC-holders tended
to use more prescription items per head and incur higher
subsidy cost than non-holders (Tables 1 and 2). The
difference (measured by the ratio) was greatest for females in
the childbearing years. This may arise because of
associations between maternity and utilisation, and
maternity and the probability of CSC-holding. Because the
age/sex profile of CSC-holders and non-holders differs,
overall rates by CSC were age/sex standardised. The
standardised CSC utilisation rate was 2.6 times the non-
CSC rate. For children, average per-item subsidy cost for
CSC-holders was lower than that for non-holders; the
reverse was true for adults (Table 3). Interpreting these
findings on unit costs is difficult because the subsidy system
is complex and the denominators in the averages exclude
items dispensed, but unprocessed by HBL.
Discussion
The results of this study, based on HBL data and a national
sample of GPs, show that CSC holders used more
prescription items per head and had higher per head subsidy
cost than non-CSC holders. This finding is consistent with a
retrospective survey of GP records carried out by Gribben
which found that the mean number of prescription items per
year for CSC holders was 6.74 compared with 4.89 for non-
holders (p<0.0001).7 Gribben also found that CSC holders
had 0.9 more GP consultations per year than non-holders,
and CSC holding remained a significant predictor of
consultation rate after controlling for age, sex, HUHC status
and five common chronic conditions. More generally, New
Zealand and United Kingdom studies have shown people on
low incomes, or with low socioeconomic status, or living in
deprived areas have overall higher GP utilisation rates.6-20
However, studies of GP utilisation amongst Maori have
generally demonstrated utilisation rates that are similar to or
lower than those of non-Maori.12, 13, 15, 16, 21, 22
Five important points must be noted in interpreting the
results of this study. First, data coding errors and errors arising
from assumptions may have introduced bias into the analysis. It
is not possible to quantify the magnitude or direction of any
such bias. Second, there is evidence that not all eligible people
apply for a CSC.5,7 Non-uptake of cards limits the usefulness of
CSCs as a means of targeting those most in need, and results in
inequitable resource allocation. Other methods of resource
allocation might be preferable, for example capitation-based
funding of primary care pharmaceutical budgets, weighted for
the socioeconomic deprivation of a practice population. Third,
the results are national averages which may hide considerable
regional variation. Other studies have demonstrated lower
levels of pharmaceutical expenditure in poor areas compared
with the national average.23,24 More emphasis should perhaps be
focused on addressing barriers to access at a local level in low-
income areas.
Fourth, the health status of various population groups,
particularly Maori and those living in socioeconomically
deprived areas, is comparatively poor.25 Reducing health
inequalities requires a range of strategies; improving access
to primary health care services is undoubtedly important,26
especially as research suggests that significant cost barriers
to access remain for many CSC holders.6 Fifth, this study
did not take health status (as a measure of need for health
services) into account. If health status were taken into
account it is possible that pharmaceutical utilisation rates
were sub-optimal amongst those most in need of services.
In conclusion, this study suggests that CSC holders had
higher pharmaceutical utilisation rates than non-holders at a
national level (but not necessarily at a local level). If non-
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Pacific populations in New Zealand carry a heavy burden
of coronary heart disease (CHD) and diabetes.1,2 Several
CHD risk factors are more prevalent amongst Pacific
people than they are amongst European New Zealanders.
They have higher mean blood pressures and a higher
prevalence of hypertension,3 microalbuminuria is more
prevalent,4 physical activity levels are lower and smoking
rates are higher.5 Also, Pacific people consume larger
quantities of food than Europeans and their diets contain
more meat and less fruit and vegetables.6 Moreover, Pacific
populations are among the most obese populations in the
world and obesity is a strong independent risk factor for
both CHD and Type-2 diabetes.7,8 In contrast, some CHD
risk factors are not as prevalent as might be expected in
such obese populations. For example, serum cholesterol
levels tend to be lower for Pacific people compared to
Europeans.9 This may be due to genetic differences and to
diet, but also, weak associations between high levels of
body fat and other CHD and diabetes risk factors have
been described.10
Heart disease and diabetes risk factors in Pacific Islands communities and
associations with measures of body fat
A Colin Bell, Postdoctoral Research Fellow;  BA Swinburn, Associate Professor, Public Health Nutrition,
Department of Community Health, Faculty of Medicine and Health Science, University of Auckland; D Simmons,
Senior Lecturer in Medicine; W Wang, Data manager, South Auckland Diabetes Project, Department of Medicine,
Middlemore Hospital; H Amosa, Project Coordinator, Department of Community Health, Faculty of Medicine and
Health Science, University of Auckland; B Gatland, Coordinator, South Auckland Diabetes Project, department of
Medicine, Middlemore Hospital, Auckland.
Aims. To describe the prevalence of obesity and other
coronary heart disease and Type 2 diabetes risk factors by
age and ethnic group in Pacific Island communities and to
determine the associations between these risk factors and
body mass index.
Methods. Cross-sectional data from two community-based
intervention projects were combined to provide
anthropometric, blood sample and blood pressure data on
1175 Pacific Islands people (467 men, 708 women) aged 20
years and over from church communities in South, Central
and West Auckland. Self-reported data on diabetes status
and leisure-time physical activity were also collected.
Results. Based on an ethnic-specific body mass index (BMI)
cut-off (> 32 kg/m2), 45% of men and 66% of women were
obese. The age-standardised prevalence of known diabetes
was 12%. Men and women aged 40 - 60 years had the
highest risk factor levels and were the most sedentary.
Tongans had higher risk factor levels than Samoans. In men,
BMI and waist circumference were associated (p<0.05), in
the direction of greater disease risk, with blood pressure and
concentrations of total cholesterol, HDL-cholesterol, LDL-
cholesterol, triglycerides, and blood glucose. In women,
these associations were similar but less consistent.
Conclusions. While these data are not representative for
all Pacific people living in New Zealand, they do show an
extremely high prevalence of obesity and significant
associations between obesity and other cardiovascular risk
factors. These communities warrant a very high priority as
part of public health efforts to address New Zealand’s
growing obesity epidemic.
Abstract
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uptake of cards and health status were taken into account,
however, it is possible that pharmaceutical utilisation rates
were sub-optimal amongst those most in need of services.
More analyses are urgently required to examine prescribing
patterns at a regional level.
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Much of the information available on the prevalence of
obesity and other CHD risk factors in Pacific populations in
New Zealand is based on the Workforce Diabetes Survey11,12
or the 1997 National Nutrition Survey (NNS97).13
Unfortunately, both surveys have their limitations in
providing the full picture of obesity in Pacific populations.
The NNS97 over-sampled Pacific people but interpretation
is hampered by a poor response rate (less than 50%) and low
sample size (273 with anthropometric data). The workforce
survey had larger numbers (n=650) and was able to examine
for differences in CHD risk between Pacific ethnic groups,
rather than assuming that risk is homogeneous.11 However,
the sampling frame was restricted to the older (40+ years),
employed Pacific workforce in Auckland and Tokoroa.
This present study pools baseline data from two large
community-based intervention projects in Auckland and
describes variations in the prevalence of obesity and other
CHD and diabetes risk factors by age and ethnic group. It
also investigates the associations between these risk factors
and measures of body fatness. While this study also has
limitations of extrapolation to the New Zealand-wide Pacific
communities, the overall aim is to provide information from
these two large studies to build a clearer picture of these
important risk patterns.
Methods
Participants. Participants came from two community-based intervention
programs, the South Auckland Diabetes Project (SADP) and the Samoan
Ola Fa’autuata Project (SOFP). The SADP was established in 1991 as a
multi-faceted program that aimed to reduce the incidence of diabetes in
New Zealand through lifestyle interventions. The Samoan Ola Fa’autauta
or ‘Life-wise’ Project was a similar community-based lifestyle program.14
Both projects worked with Pacific Islands church groups in South,
Central and West Auckland. The selection of churches for interventions
was non-random but all adults from each church community were invited
to take part. There was no specific selection for those who were obese or
those with diabetes. The church community was defined as those people
whose names were on the church roll plus their household members.
From these membership lists, the baseline response rate for the SADP
was 60% and for the SOFP it was 81%.
This analysis includes self-identified Pacific Islands people, aged 20
years and over who had complete anthropometric data at baseline. A total
of 1175 people, 725 (287 men, 438 women) from the SADP and 450 from
the SOFP (180 men, 270 women). Where our data from these Church
Intervention Surveys (CIS) were compared with the National Health and
Nutrition survey, we included BMI data from an additional 117
adolescent’s aged 15 - 19 years. The SOFP was given ethical approval by
the University of Auckland Human Subjects Ethics Committee and the
SADP by the Auckland Area Health Board Ethics Committee.
Data collection. Both projects collected data at a series of health
surveys on church premises between 1991 and 1996. Participants received
information sheets, translated if necessary, and a brief presentation
explaining the project. Consent was obtained from all participants
(interpreters were available). Standardised techniques were used to
measure weight, height, waist, and hip circumference.15 The SOFP used
Seca electronic scales (model 708) with an attached stadiometer to
measure weight and height after removing heavy clothing and shoes. The
SADP used the same standardised techniques, a portable stadiometer
(CMS, London) and Salter spring scales. The scales were calibrated
regularly.  Non-stretch fibreglass tapes were used to measure waist and
hip circumference. Waist circumference was measured horizontally
through a point midway between the top of the iliac crest and the bottom
of the ribs. Hip circumference was measured at the largest posterior
extension of the buttocks.
Non-fasting venous blood samples were collected, stored and analysed
for blood lipids, glucose and fructosamine levels by Medlab Ltd. Samples
were measured using Roche Diagnostic protocols. Blood pressure was
measured twice in the sitting position with a standard mercury
sphygmomanometer using Korotkoff phase 1 and 5 sounds for systolic
and diastolic blood pressure respectively. Oversize cuffs were used for
large arms. Participants were considered sedentary if they did no
moderate or vigorous  activity during a normal week.
Statistical Analysis. BMI was calculated as weight (kg) divided by
height (m) squared. Pacific specific BMI cutoffs were used to define
overweight (26 kg/m2 ≥ BMI < 32 kg/m2) and obesity (BMI ≥ 32 kg/
m2).16 The data were stratified by gender and analysis of variance was
used to calculate adjusted age- and ethnic-specific means. Age-
standardised means (Table 1) were calculated by the direct method
using Segi’s world population for those aged ≥ 20 years.17 Multiple
regression was used to test for linear associations between age and blood
cholesterol, triglyceride, glucose and blood pressure. A second model
that included a quadratic term (age-squared) was used to test for curvi-
linearity. With the exception of the ethnic group analysis, indicator
variables were used to adjust for confounding by ethnic group and to
adjust for systematic differences in risk factor levels between the two
projects.
Table 1. Association between age and anthropometric, biochemical and blood pressure measurements, mean (SEM), in Pacific Islands men. The
prevalence of obesity, sedentary leisure time activity and known diabetes is also given.
Age Age group (years) P for linear P for quadratic
Standardised* 20-29 30-39 40-49 50-59 ≥ 60 term† term‡
Anthropometry, n 467 106 97 120 94 50
Weight, kg 97.6 (8.9) 96.7 (l.9) 98.3 (2.0) 99.9 (l.8) 99.0 (2.1) 94.7 (2.6)   0.69   0.0006
Height, cm 172.9 (3.0) 177.1 (0.6) 174.1 (0.7) 171.5 (0.6) 170.9 (0.7) 168.9 (0.9) <0.0001   0.02
Body mass index, kg/m2 32.6 (2.7) 30.8 (0.6) 32.3 (0.6) 33.9 (0.5) 33.9 (0.6) 33.2 (0.8)   0.0004 <0.0001
Waist, cm 103.9 (6.9) 96.7 (l.5) 103.0 (1.5) 107.2 (l.4) 108.2 (l.6) 108.3 (2.0) <0.0001 <0.0001
Hip, cm 110.7 (5.6) 109.9 (l.2) 109.7 (l.3) 112.1 (1.1) 111.2 (l.3) 111.4 (l.6)   0.33   0.13
BMI > 32 kg/m2, % 45 32 37 59 56 47 - -
Non-fasting lipids, n 352 67 69 94 79 43
Total cholesterol, mmol/L 5.80 (0.49) 5.28 (0.13) 5.87 (0.13) 6.27(0.11) 6.08(0.13) 5.74(0.16) 0.002 <0.0001
HDL, mmol/L 1.10 (0.14) 1.14 (0.04) 1.13 (0.04) 1.09(0.03) 1.05(0.03) 1.07(0.04) 0.09   0.62
LDL,§ mmol/L 3.67 (0.44) 3.17 (0.12) 3.68 (0.13) 4.08(0.11) 3.94(0.12) 3.74(0.14) 0.0002 <0.0001
Total:HDL ratio 5.56 (0.78) 4.83 (0.21) 5.67 (0.21) 5.98(0.18) 6.03(0.20) 5.65(0.25) 0.003   0.002
Triglyceride,|| mmol/L 2.40 (l.06) 2.17 (0.28) 2.65 (0.28) 2.77(0.25) 2.51(0.27) 2.00(0.34) 0.54   0.02
Non-fasting glucose, n 402 81 84 105 88 44
Glucose,||  mmol/L 6.37 (l.61) 4.96 (0.39) 5.36 (0.40) 6.42 (0.35) 7.60 (0.39) 8.47(0.50) <0.0001 0.07
Blood pressure, n 414 86 87 110 87 44
Systolic, mmHg 136.2 (8.4) 126.4 (2.0) 130.0 (2.0) 134.1(1.8) 145.3 (2.0) 152.3 (2.6) <0.0001   0.32
Diastolic, mmHg 86.8 (5.6) 80.9 (l.3) 84.2 (l.4) 87.9 (l.2) 92.2 (l.4) 92.9 (l.8) <0.0001 <0.04
Leisure time activity, ¶n 342 94 75 75 66 32
Sedentary, % 22 14 19 31 24 28 - -
Diabetes prevalence, n 490 114 104 121 98 53
Known diabetes, % 12 2 3 7 21 36 - -
Age standardised to Segi’s world population. †Model 1. Age was the independent continuous variable and variables for ethnic group and study were included in the model.
‡Model 2. Same as model 1 with the quadratric term (age squared) included. §Total n for LDL = 310 because of triglyceride levels > 4 mmol/L. ||The natural logs of
triglyceride and glucose were used in the models. ¶Leisure time activity data were not collected from 1995 onwards in the South Auckland Diabetes project.
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Associations between body size and lipids, glucose and blood pressure
were tested using analysis of variance. Multiple regression was used where
the variables were treated continuously. Triglyceride and glucose
variables were log transformed to improve the normality of the
distributions. Analyses were carried out in SAS version 6.10 (SAS
Institute, Cary, NC, USA).
Results
Participants in this CIS study were older (mean age 42 years
for men, 41 years for women) and more likely to be female
(60% of participants) than the general Pacific Islands
population (1996).18 Most were Samoan (64%) or Tongan
(26%) whereas approximately 50% of the general Pacific
Islands population identify themselves as Samoan and 14%
as Tongan. Compared to the overall distribution of
occupations in New Zealand (1991),19 the distribution of
occupations for Samoans in the SOFP project was shifted to
the lower income end (p<0.001).
Based on our results, 81% and 86% of Pacific Islands men
and women aged 15 years and over were either overweight (26
kg/m2 ≥ BMI < 32 kg/m2) or obese (BMI ≥ 32 kg/m2), with
44% of men and 58% of women being obese (note: these are
not age-standardised). We compared these percentages with
results from the National Nutrition Survey in Figures 1 and 2.
Compared to the NNS97, we observed a considerably lower
combined prevalence of overweight and obesity for young
Pacific males (87.6% vs 55.8%). On the other hand our
estimates of obesity were higher (44.8% vs 27.4%) for males
aged 25-44 years and overweight lower than for the NNS97.
Differences were also noted for females aged 25-44 years
(61.5% obese vs 34% obese; Figure 2).
Tables 1 and 2 present associations between age and CHD
and diabetes risk factors for men and women aged 20 years
and over. Pacific men had an age-standardised mean BMI of
32.6 kg/m2. Most risk factors were higher in the older age
groups, although mean weight, BMI, obesity prevalence, total
cholesterol, LDL, the total: HDL ratio, triglycerides and
sedentary leisure time activity were lower in the 60+ age
group than the younger two decade groups. Women (Table 2)
had a higher aged- standardised mean BMI (34.8 kg/m2) than
men and a higher prevalence of obesity (60% with a BMI ≥
32kg/m2). As with men, most risk factor levels were lower in
the 60+ age group than the younger age groups. Overall, 12%
of men and women reported having Type-2 diabetes and
approximately one-quarter did no leisure time physical
activity during a normal week.
A comparison of risk factors by ethnic group is given in
Table 3. Tongans had the highest mean BMI and the
highest prevalence of obesity. Their lipid profiles were
significantly more atherogenic than Samoan profiles. Also,
Tongan men had significantly higher mean glucose levels
and Tongan women were significantly more likely to do no
leisure time physical activity.
Table 4 shows relationship between BMI and waist
circumference with other CHD and diabetes risk factors.
For men, each risk factor, with the exception of HDL
(where the association was inverse), was higher at higher
quartiles of BMI. A similar, although less consistent pattern
was observed between these risk factors and quartiles of
waist circumference. Where BMI and waist circumference
were treated continuously, both were positively (p<0.05)
associated with each risk factor. There was an inverse
association with HDL. These models were re-run (not
shown) including squared terms for BMI or waist. None of
the squared terms was significant.
For women, the variation in these risk factors with
quartiles of BMI and waist was not as marked as it was for
men. Mean total and LDL cholesterol and glucose levels
differed little although mean systolic and diastolic blood
pressure was higher with each quartile of BMI. Using
continuous data, only the total:HDL cholesterol ratio, (log)
triglycerides and systolic and diastolic blood pressure were
positively associated with BMI. There was a significant
negative association between HDL and BMI. Total
cholesterol, the total:HDL cholesterol ratio, (log)
triglycerides, glucose, and diastolic blood pressure were all
positively associated with waist circumference in women.
When the squared terms for BMI and waist were included in
these models, negative associations (p<0.05 for BMI) were
observed for cholesterol, the total:HDL cholesterol ratio,
LDL and (log) triglyceride concentrations (not shown).
Discussion
These cross-sectional analyses of CHD and diabetes risk
factors came from church-based Pacific populations and are
not, therefore, a representative sample. However, the sample
size was large (total n = 1175) and the results are probably as
characteristic of New Zealand’s Pacific Islands population as
Figure 1. Overweight and obesity in three age groups as reported by
the Church Intervention Surveys (CIS) and the National Nutrition
Survey 1997 (NNS97): Pacific males.
Figure 2. Overweight and obesity in three age groups as reported by
the Church Intervention Surveys (CIS) and the National Nutrition
Survey 1997 (NNS97): Pacific females.
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the National Nutrition Survey which was smaller and had a
lower response rate. The data show that risk factors for
CHD and diabetes are very high, especially in the 40-60 year
age range and amongst the most obese.
The prevalence of obesity in Pacific populations has been
comprehensively reviewed by Hodge et al for populations
living in the Pacific Islands.20 The review indicated that
Pacific populations are amongst the most obese in the world.
Western Samoans,  for example, had a higher prevalence of
obesity than native Hawaiians and Pima Indians.21,22 In this
study, we found that Pacific people living in New Zealand
have an even higher prevalence. Our observation that
women had a higher prevalence of obesity than men is
consistent with findings from studies in Western Samoa and
New Zealand. Schaaf et al observed no significant
differences in BMI between Cook Islands Maori, Samoans,
Table 2. Association between age and anthropometric, biochemical and blood pressure measurements, mean (SEM), in Pacific Islands women.
The prevalence of  obesity, sedentary leisure time activity and known diabetes is also given.
Age Age group (years) P for linear P for quadratic
Standardised* 20-29 30-39 40-49 50-59 ≥60 term† term‡
Anthropometry, n 708 187 169 164 111 77
Weight, kg 91.2 (9.6) 87.8 (l.6) 93.3 (l.6) 96.8 (l.7) 93.7 (l.9) 85.6 (2.3)   0.84 <0.01
Height, cm 161.5 (2.9) 164.0 (0.5) 163.0 (0.5) 161.4 (0.5) 160.0 (0.6) 157.4 (0.7) <0.01   0.06
Body mass index,  kg/m2 34.8 (3.3) 32.1 (0.5) 34.9 (0.6) 37.0 (0.6) 36.4 (0.7) 34.2 (0.8) <0.01 <0.01
Waist, cm 102.1(6.9) 94.0 (1.1) 101.0 (1.2) 105.2 (1.2) 108.4 (1.4) 106.7 (1.7) <0.01 <0.01
Hip, cm 115.5 (6.9) 111.8 (1.1) 115.0 (1.2) 118.9 (1.2) 119.3 (1.4) 114.9 (1.7) <0.01 <0.01
BMI > 32 kg/m2, % 60 41 64 72 73 58 - -
Non-fasting lipids, n 548 130 120 148 94 56
Total cholesterol, mmol/L 5.46 (0.46) 4.84 (0.09) 5.09 (0.09) 5.44 (0.09) 6.04 (0.10) 6.33 (0.13) <0.01 0.05
HDL, mmol/L 1.22 (0.15) 1.26 (0.03) 1.19 (0.03) 1.20 (0.03) 1.23 (0.03) 1.19 (0.04)   0.41 0.55
LDL,§ mmol/L 3.47 (0.39) 2.96 (0.08) 3.20 (0.08) 3.48 (0.07) 3.83 (0.10) 4.21 (0.12) <0.01 0.06
Total:HDL ratio 4.70 (0.62) 4.05 (0.12) 4.48 (0.12) 4.70 (0.12) 5.16 (0.14) 5.50 (0.18) <0.01 0.15
Triglyceride,||  mmol/L 1.77 (0.53) 1.49 (0.10) 1.63 (0.11) 1.79 (0.10) 2.04 (0.12) 2.08 (0.15) <0.01 0.02
Non-fasting glucose, n 613 147 146 156 98 66
Glucose,|| mmol/L 6.67 (2.25) 5.28 (0.41) 5.89 (0.41) 6.62 (0.41) 8.86 (0.49) 7.81 (0.59) <0.01 0.18
Blood pressure, n 631 152 150 156 103 70
Systolic, mmHg 132.0 (8.9) 119.5 (l.6) 123.8 (l.6) 133.7 (l.6) 145.9 (l.9) 145.9 (2.3) <0.01   0.11
Diastolic, mmHg 82.6 (5.8) 76.1 (1.0) 79.7 (l.1) 85.6 (l.1) 88.2 (l.2) 87.4 (l.5) <0.01 <0.01
Leisure time activity, ¶n 478 149 109 99 70 51
Sedentary, % 27 25 29 29 26 29 - -
Diabetes prevalence, n 732 194 175 167 118 78
Known diabetes, % 12 1 4 8 25 31 - -
*Age standardised to Segi’s world population. †Model 1. Age was the independent continuous variable and variables for ethnic group and study were included in the model.
Model 2. Same as model 1 with the quadratric term (age squared)  included. §Total n for LDL = 514 because of triglyceride levels > 4 mmol/L. || The natural logs of
triglyceride and glucose were used in the models. ¶Leisure time activity data were not collected from 1995 onwards in the South Auckland Diabetes project
Table 3. Ethnic differences in anthropometric, biochemical and blood pressure measurements, mean (SEM). Differences in the prevalence of
obesity, sedentary leisure time activity and known diabetes are also given.
Men Women
Samoan Tongan Other PI* Samoan Tongan Other PI*
Anthropometry, n 286 140 41 474 167 67
Weight, kg 94.5(l.1) 101.9 (1.8)b 96.7(2.8) 89.4(0.9) 95.9(1.7)b 80.0(2.4)
Height, cm 171.4(0.4) 174.4 (0.6)c 171.7(0.9) 160.9(0.3) 162.8(0.5)b 159.8(0.7)
Body mass index, kg/m2 32.1(0.3) 33.5 (0.6)a 32.7(0.8) 34.5(0.3) 36.1 (0.6)a 34.2(0.8)
Waist, cm 103.1(0.8) 105.0(1.4) 105.9(2.1) 101.0(0.6) 105.7 (1.3)b 102.5(l.7)
Hip, cm 108.9(0.7) 111.5(l.1) 112.2(l.7) 115.0(0.6) 117.4(l.3) 115.6(l.7)
Obesity, % BMI ≥30 kg/m2 63 68a 51 73 75a 76
Obesity, % BMI >32 kg/m2 46 49 42 60 59 66
Non-fasting lipids, n 218 96 38 374 120 54
Total cholesterol, mmol/L 5.58(0.07) 5.96 (0.12)a 6.00 (0.17)a 5.44(0.05) 5.61(0.10) 5.59(0.13)
HDL, mmol./L 1.16(0.02) 1. 03 (0.03)b 1.09(0.04) 1.31(0.01) 1. 19 (0.03)b 1. 14 (0.04)c
LDL,† mmol/L 3.52(0.07) 3.85 (0.12)a 3.80(0.16) 3.37(0.05) 3.62 (0.09)a 3.62(0.12)
Cholesterol/HDL ratio 5.03(0.11) 6.15 (0.19)c 5.72 (0.26)a 4.38(0.07) 4.89 (0.13)b 5.06 (0.17)b
log Triglyceride, mmol/L 2.16(0.15) 2.82 (0.26)a 2.28(0.35) 1.69(0.06) 1.82(0.11) 1.90(0.14)
Non-fasting gucose, n 232 130 40 406 148 59
Glucose, mmol/L 6.37(0.22) 7.29 (0.3 5)a 6.04(0.53) 6.75(0.23) 6.79(0.43) 7.01(0.59)
Blood pressure, n 242 131 41 420 149 62
Systolic, mmHg 134.6(l.1) 137.2(l.8) 141.0 (2.7)a 131.4(0.9) 132.4(l.7) 137.5 (2.3)a
Diastolic, mmHg 85.7(0.8) 86.2(1.2) 90.9 (1.8)a 82.4(0.6) 81.5(l.1) 8 6.3 (1.5)a
Leisure time acitivity,‡ n 231 96 15 347 106 25
Sedentary, % 24 11 60b 25 36b 24
Diabetes prevalence, n 302 145 43 494 171 67
Known diabetes, % 11 11 12 10 9 13
*Other Pacific Islands (PI) ethnic groups, Cook Islands Maori (n=51), Niuean (n=20), and mixed Pacific Islands ethnic group (n=39). †Total n for LDL = 824 due to
triglyceride levels > 4 mmol/L. ‡Leisure time activity data were not collected from 1995 onwards in the South Auckland Diabetes Project. a,b,c Significantly different from
Samoan ethnic group at ap<0.05, bp<0.01, cp<0.0001 adjusted for age group and study.
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Tongans and Niueans.11 We found that Tongan men and
women were bigger than their counterparts from other
islands.
The lipid profiles of Pacific men and women in the
current study were less atherogenic than those reported in
the National Nutrition Survey,13 and the Workforce
Diabetes Survey.11 The attenuation of risk factor levels in
older Pacific people has previously been described23,24 and
probably reflects selective mortality of high risk individuals
or the cohort effect of a relatively lower risk group of
individuals now reaching older age.2 The age-standardised
prevalence of known diabetes (12%) was similar in these
church communities to the prevalence observed in a
household survey of inner urban South Auckland.25 Systolic
and diastolic blood pressure levels were comparable to those
observed in Pacific members of a Seventh-Day Adventist
church.24 Also, similar increases in blood pressure with age
have been observed in Pacific Islands people in the
workforce.3,26 The number of people who were sedentary
during leisure-time was high in these communities. Previous
New Zealand studies found that Pacific people were less
involved in leisure-time activities than Maori or European
and that Pacific women were less active than men.5
Body size was adversely associated with other CHD and
diabetes risk factors.  However, the associations were not as
strong as those observed for European New Zealanders,24 and
other less obese populations.27 Moreover, for Pacific women,
there was evidence of attenuation between BMI and blood
cholesterol and triglycerides at the upper end of the BMI
distribution. Similar findings have been observed in studies of
Samoans in Western Samoa and American Samoa, and
Micronesian Nauruans.28,29 The poor associations observed
were attributed to extreme obesity in these populations. This
suggests that these populations have reached a level of obesity
above which the impact of total fat or intra-abdominal fat on
CHD and diabetes risk factors becomes less apparent.
There are a number of limitations to this study. As mentioned
above, neither the church communities nor the participants were
randomly selected and therefore the results may not readily be
generalised to New Zealand’s wider Pacific population. Numbers
in the studies were lower than they could have been for several
variables because providing a blood sample was voluntary and up
to 30% declined. Finally, combining the results of two separately
conducted studies is not ideal methodology although we tried to
overcome this limitation by adjusting for risk factor differences
between the projects.
The SADP and the SOFP were both designed to reduce
CHD and diabetes risk factors in these church communities
and both had some success.30,31 The high prevalence of
obesity and other risk factors at baseline suggests that these
interventions were not only warranted, but long overdue in
the effort to bring the health status of these communities in
line with that of other New Zealanders. Future efforts to
contain the rising prevalence of obesity in New Zealand
need to give priority to Pacific People.
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VIEWPOINT
Should decisions on treatment be based on absolute benefit rather than absolute
risk?
Bernard M Y Cheung, Associate Professor; Cyrus R Kumana, Professor, Division of Clinical Pharamcology and
Therapentics, Department of Medicine, The University of Hong Kong, Hong Kong.
NZ Med J 2001; 114: 214-5
With the escalation of treatment costs, who to treat and
when to treat become increasingly important questions for
the clinician and health care provider. For example, lipid
lowering therapy using statins has been shown to reduce
cardiovascular events even in asymptomatic individuals.
However, widespread use of these drugs in asymptomatic
low risk individuals is costly and the magnitude of benefit is
likely to be small. We have previously compared the use of
relative risk reduction (RRR) and number needed to treat
(NNT) to describe coronary heart disease (CHD) event
prevention following long-term intervention with statins
under different circumstances in similarly aged adults.1
NNTs indicate how many individuals must incur the
expense and inconvenience of treatment, and risk of adverse
effects to save one person from experiencing the defined
event over a given period of time. The higher the baseline
risk, the smaller the corresponding NNT.
Consensus treatment guidelines drawn up by experts in recent
years have adopted the concept of baseline risk in combination
with the projected RRR to assess the necessity and urgency of
treatment. The baseline risk can be estimated from the
Framingham equation2 or from tables.3,4 With regard to the
benefits of statins and antihypertensives, RRRs are fairly similar
at different levels of baseline risk. The risk of a patient having a
cardiovascular event without treatment can be used as a basis for
deciding whether somebody needs drug treatment or not. For
example, a young woman with hypertension or hyperlipidaemia
only may not require drug treatment in the first instance because
of her inherently low cardiovascular risk. On the other hand, a
60- year old man who is a smoker and has a family history of
cardiovascular disease may very well require treatment of
hypertension and hyperlipidaemia even if the blood pressure and
cholesterol levels are only moderately elevated.
Consideration of absolute risk reduction (ARR) has also
been a key innovation in the new British Hypertension
Society Guidelines for the management of hypertension.5,6
One of its recommendations is a formal estimation of a
subject’s ten year CHD risk in order to decide whether or
not to treat patients with mild hypertension. Recourse to
ARR in preference to RRR is certainly a laudable
development. However, this approach does not take age
into account. As elderly patients have inherently higher
risks of disease and death, treatment decisions based on
risk alone will always favour the elderly. An elderly person
with very mild hypertension readily attains the 1.5% or so
annual risk of events that mandates treatment. A young
person even with multiple risk factors, may not reach the
same level of annual risk. If treatment decisions are to be
based solely on risk, then implementing this strategy will
lead to therapeutic decisions that run contrary to common
sense. The problem is that knowing the baseline risk, (i.e.
the risk of no treatment), is not enough. One also needs
to know the benefits of treatment. In this regard, the
benefit is directly related to life expectancy. A
cardiovascular death at 50 represents, say 20 years of life
lost, whereas a death at 75 could represent only five lost
years.
Unfortunately, ARR has been confused with absolute
benefit. The two are not equivalent. Risk is the likelihood of
the occurrence of an unfavourable event whereas in
preventive medicine, the benefit is the magnitude of the loss
or harm averted. One is a probability; the other is a quantity.
Total benefit depends on ARR and the value of preventing
one unfavourable event. The total amount of benefit is more
important than how frequently the instalments come. A
minimal benefit can never be attractive, even if there is a
99% chance of gaining it. On the other hand, a tiny risk, say
1%, cannot always be ignored, especially if the penalty is
something unpleasant. We take out fire insurance on our
home because we cannot afford the consequences of a fire
even if the risk is extremely remote. What is actually at risk
matters just as much as how great the risk is.
For moral, ethical and religious reasons, we tend to value
life and well-being as the same in everyone. Although the
immediate consequences of a stroke are equally devastating
regardless of age, the long-term consequences, however, are
much worse when it afflicts a 40-year old. Hence, prevention
of the same event gives rise to different magnitudes of
benefit depending on a person’s age and circumstances. Any
decisions on treatment based on absolute risk alone will miss
this important dimension in a therapeutic decision.
Clinicians routinely make use of such information
instinctively and intuitively. Guidelines that exclude such
considerations are mechanical, imperfect and misleading.
There is also the view that treatment of hypertension or
hyperlipidaemia can be delayed until the absolute annual risk
crosses a certain threshold. Most patients as consumers and
clinicians concerned with preventive medicine, would reject
such a view. Untreated hypertension or hypercholesterolaemia
damage the heart, vasculature and kidneys so that early
preventive measures are warranted. Coronary artery disease,
heart failure and renal failure are often asymptomatic until an
advanced stage.
In the absence of a full assessment of risk and benefit, basing
treatment decisions on the cardiovascular risk alone is
inadequate. This policy will tend to prolong life in the
extremely elderly whilst forgoing the prevention of premature
deaths through withholding treatment in the young. One
solution might be to use the NNT to gain one year of life (or
better still, one quality adjusted life year or QALY), to evaluate
the effectiveness of an intervention. The elderly have a lower
life expectancy and hence the life-years gained will be fewer
compared to younger persons. The paradox arising from
equating death in the elderly with premature death in the
young can therefore be resolved. There are already plans to
express clinical trial results in terms of average duration of life
gained (ADLG).7 As benefits resulting from medical
intervention vary with age, increasingly we will have to consult
life tables as a fairer basis for the allocation of resources and
priorities.
Pioneering attempts have been made at calculating the gain
in event-free life years arising from lipid lowering therapy.8 As
soon as one considers the lifetime risk of cardiovascular disease,
it becomes apparent that most events occur before people reach
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Recommending particular treatment options: the vitamin K experience
Jonathan Coates, Senior Solicitor, Buddle Findlay, Wellington.
NZ Med J 2001; 114: 215
This column has previously discussed what information
must be given to a patient in order for the patient to be
sufficiently  informed about an intervention, and for the
consent to be valid. What, however, are a health
professional’s obligations where there are diametrically
opposed treatment options? Should the health
professional simply discuss the benefits and risks
associated with the various options, or should he
recommend one? How far should the patient be
encouraged to accept a particular treatment option?
These issues can be answered with reference to a New
Zealand case involving the death of a twelve day old baby.
The baby’s parents had conducted their own research
(including using the internet) into the appropriateness of
vitamin K administration. At the parent’s request, no vitamin
K was administered. The baby died from haemorrhage.
The law allows parents to either consent to or refuse
administration of vitamin K to their baby. In reaching that
decision, parents have the right to be provided with
information that a reasonable parent, in the circumstances,
would expect to receive. This will include an explanation of
the options available together with expected risks, side
effects, benefits and costs of each option.1 Studies have
raised the possibility of a link between intra-muscular
vitamin K and increased risk of acute lymphoblastic
leukaemia. The link has not been proven and would not
need to be raised by the health professional if the parents did
not question the appropriateness of vitamin K. If the parents
however indicate a concern about vitamin K, the risks
associated with refusing vitamin K are sufficiently material
to require the health professional to warn the parents.
Should the health professional do more than just explain the
risks, and actually encourage the parents to consent to
administration of vitamin K? On the face of it, the law only
requires health professionals to recommend a treatment option if
they are expressly asked to do so by the parents (or patient).2 So if
a patient does not ask for a recommendation, the general rule is
that a recommendation need not be offered. However, in order
to ensure that the patient/parent is fully informed, the health
professional must also provide “any other information required
by legal, professional, ethical, and other relevant standards”.3
Professional and ethical standards probably dictate that ‘other
information’ which must be provided includes encouragement
that vitamin K should be administered. At this point in time, the
weight of research supports such a conclusion. Such
encouragement would be consistent with a consensus statement
issued by the Paediatric Society of New Zealand, together with a
number of other professional organisations, on the subject.4
Health professionals who encourage parents to consent to
the administration of vitamin K must be careful that they do
not go too far. An essential element of a valid consent is that it
is given voluntarily. Any duress will invalidate the consent.
The final decision must rest with the parents.
Issues such as this will become more frequent with the
dissemination of information on the internet. The quality of
information on the internet is variable and lay people will not
always be able to assess its accuracy. Health professionals must
get used to discussing treatment options with patients. They
should consider asking the patient whether he or she would like
a recommendation on the treatment options. Health
professionals will want to help their patients make decisions
that will lead to the most appropriate treatment, without
becoming paternalistic and invalidating the consent. It will not
always be an easy tightrope to walk.
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an age at which they have a high annual cardiovascular risk.
Individuals at high risk are mostly elderly and are only the tip of
the iceberg. Using a hypothetical cohort of 100 non-smoking
men as illustration, Ulrich et al showed that the gain in life
years per treatment year was maximal at age 40, which was
therefore thought to be the optimal age of starting treatment.8
However, this ‘optimal’ age may vary from person to person,
depending on cardiovascular risk factors and life expectancy.
There are many imponderables involved in calculating life
expectancies and risks, so we do not necessarily expect this
method of therapeutic decision to gain currency. On the other
hand, the event-free life gained from treatment varies little
from age 20 to 70.8,9 Treating 30 year olds will save fewer lives
but gain as many life years as treating 70 year olds. Viewed
from this perspective, using the absolute risk to determine
necessity or priority of treatment is a seriously flawed backward
step in the prevention of cardiovascular disease. The way
forward must be to base therapeutic decisions on the benefit
the patient is likely to derive from the treatment.
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